

**From:**

[REDACTED]

**Sent:** 30 November 2012 07:17

**To:** TA Comm B

**Cc:** [REDACTED]

**Subject:** NICE: MTA - Asthma - omalizumab (rev TA133, TA201) [ID482]- ACD:

Dear NICE

Thank you for the opportunity to comment on the appraisal consultation document and evaluation report for the above multiple technology appraisal.

**I wish to confirm that the Department of Health has no substantive comments to make, regarding this consultation.**

Many thanks and best wishes

[REDACTED]

NICE Sponsor Team  
Department of Health

The original of this email was scanned for viruses by the Government Secure Intranet virus scanning service supplied by Cable&Wireless Worldwide in partnership with MessageLabs. (CCTM Certificate Number 2009/09/0052.) On leaving the GSi this email was certified virus free.

Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.

---

Delivered via MessageLabs

---